Evolution of the Average Target: Valneva SE Pref.

Data source: Valneva SE(VLA)

Evolution of the Target Price: Valneva SE Pref.

Data source: Valneva SE(VLA)

Changes in Analyst Recommendations: Valneva SE Pref.

Data source: Valneva SE(VLA)
24e915348dae04ecf3eed19c8fbe5.HJllJLzC9a-nMcuXYBq_q_fPqfK1wujTEHgKWzyrJDs.b9cUXtH3g8TUBY7GN1vnxq2A3p3ErIqBJ0xgIw_IUkhx9V1z1JSw1ulUgg~dfdbcb1755b061ab78737c5080491766
08-11 TD Cowen Initiates Valneva at Buy Rating, With $12 Price Target MT
05-13 French Analyst Ratings: Aramis and Valneva penalized following profit warnings Zonebourse
04-30 Schneider Electric, Capgemini, Societe Generale... stocks to watch today in Paris Zonebourse
04-22 Goldman Sachs Downgrades Valneva to Sell From Neutral, Adjusts Price Target to $4.90 From $7.50 MT
04-22 French Analyst Ratings: Thales, Vallourec and Valneva in the Spotlight Zonebourse
03-18 Valneva heads for fourth consecutive gain following annual results Zonebourse
01-20 Stifel Reiterates Buy Rating and Price Target on Valneva Zonebourse
01-06 Valneva, Biggest Gainer on SBF 120 and SRD at Close of Tuesday, January 6, 2026 Zonebourse
01-06 Valneva Surges on Positive Broker Comments Zonebourse
01-06 CAC 40 Lags Behind; Valneva in Demand Zonebourse
01-06 Valneva Posts Strongest Midday Gain on SBF 120, Tuesday, January 6, 2026 Zonebourse
01-06 Stock of the Day in Paris – Valneva Bolstered by Stifel Zonebourse
01-06 Stifel Raises Price Target for Valneva Zonebourse
01-06 Analysts' calls of the day: Bernstein favors Thales over BAE Systems and Dassault Aviation Zonebourse
11-20 Stifel Reiterates Buy Recommendation on Valneva Zonebourse
11-04 Valneva SE Announces Positive Results of Its Phase 1 Clinical Trial Investigating the Safety and Immunogenicity of VLA1601 CI
03/09/25 Valneva publishes positive data for its Lyme disease vaccine candidate, stock rises RE
26/08/25 Valneva: Stifel Adjusts Price Target Following FDA Suspension of Ixchiq License Zonebourse
26/08/25 Valneva: Stifel adjusts target price Zonebourse
12/08/25 Valneva: Oddo BHF confirms 'outperform' rating Zonebourse
14/07/25 Valneva Shares Surge After EMA Lifts Restriction on Chikungunya Vaccine RE
13/08/24 Valneva: Oddo BHF confirms its recommendation on the stock Zonebourse
24/06/24 Valneva rises after Canadian approval for its chikungunya vaccine RE
05/02/24 Valneva: Oddo BHF confirms its recommendation on the stock Zonebourse
02/01/24 Valneva: Oddo BHF remains positive Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+16.44%
+22.14%
+17.84%
+6.62%
+25.91%
+18.49%
+49.69%
+8.86%
+71.01%
Average +26.33%
Weighted average by Cap. +23.02%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.710EUR
Average target price
6.193EUR
Spread / Average Target
+128.52%
High Price Target
12.00EUR
Spread / Highest target
+342.80%
Low Price Target
2.150EUR
Spread / Lowest Target
-20.66%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. VLA Stock
  4. VLAP Stock
  5. Consensus Valneva SE Pref.